Search Results

Lobe Sciences Ltd., a biopharmaceutical company focused on developing transformative medicines to treat rare diseases and Clearway Global, LLC, a wholly owned subsidiary of Sancilio & Company, a pharmaceutical services company focused on value creation strategies, are pleased to announce a change in control of the Company and several enhancements to its ongoing growth strategy.

StageZero Life Sciences announced its first quarter financial results for the three months ended March 31, 2024, and will provide an update on its business operations.

Specac, Ltd announced today the acquisition of Harrick Scientific, Inc.

SMITM CAPITAL MARKETS LTD, has announced a significant agreement with Mid-Atlantic BioTherapeutics, Inc. (MABT), a clinical-stage ready US biopharmaceutical company.

Enzyvant Therapeutics, Inc. and Altavant Sciences, Inc., both wholly owned subsidiaries of Sumitovant Biopharma Ltd., today announced a merger to form a biopharmaceutical company focused on delivering life-altering therapies for people with rare diseases.

Lobe Sciences Ltd., a biopharmaceutical company focused on developing transformative medicines to treat diseases with unmet medical needs and rare diseases announced the evaluation of strategic alternatives to improve shareholder value.

ImmunoPrecise Antibodies Ltd., a leader in AI-driven biotherapeutic research and technology, announces that its subsidiary, BioStrand, has been honored with the prestigious 2024 Impact Award, sponsored by InterSystems.

Meihua International Medical Technologies Co., Ltd., a reputable manufacturer and provider of Class I, II and III disposable medical devices with operating subsidiaries in China, announced that its board of directors has approved and authorized a share repurchase program of up to $3 million of the Company’s outstanding ordinary shares.

Lobe Sciences Ltd. today announced that Frederick D. Sancilio Ph.D. has agreed to join its Board of Directors.

Tiziana Life Sciences, Ltd. today announced that the U.S. Food and Drug Administration (FDA) has allowed intranasal foralumab to be used under an Expanded Access (EA) IND in its first patient with moderate Alzheimer’s disease.